Aprea Therapeutics, INC Form 4 insider transactions

Director Marc Duey acquired 30,000 shares of Aprea Therapeutics at $4.39 per share on October 16, 2024.

Aprea Therapeutics' CEO, Oren Gilad, recently acquired 250 shares of common stock and disclaims beneficial ownership of shares held by his children.

Director Marc Duey acquired 190 shares of Aprea Therapeutics at $2.58 per share on October 14, 2024.

John P. Hamill, SrVP/CFO/Prin Fin & Acct Ofcr of Aprea Therapeutics, Inc., acquired 50 shares of common stock at a price of $2.4638 on October 11, 2024.

Director Bernd R. Seizinger of Aprea Therapeutics, Inc. (APRE) purchased 10,000 shares of common stock at an average price of $2.68 on October 11, 2024.

Aprea Therapeutics' CEO, Oren Gilad, recently purchased additional shares of the company's common stock in the open market.

John P. Hamill, SrVP/CFO/Prin Fin & Acct Ofcr of Aprea Therapeutics, recently purchased 450 shares of the company's common stock at an average price of $2.61.

Director Bernd R. Seizinger reported the acquisition of common stock and stock options in Aprea Therapeutics, Inc. on June 20, 2024.

Director Rifat Pamukcu reported the acquisition of common stock and stock options in Aprea Therapeutics, Inc. on June 20, 2024.

Director Richard Peters acquired 1,045 shares of common stock and 4,185 stock options in Aprea Therapeutics on June 20, 2024.

Director John Henneman III acquired 1,045 shares of common stock and 4,185 stock options in Aprea Therapeutics on June 20, 2024.

Director Michael Grissinger reports acquisition of restricted stock units and stock options in Aprea Therapeutics.

Director Marc Duey received restricted stock units and stock options from Aprea Therapeutics on June 20, 2024.

Chief Medical Officer of Aprea Therapeutics, Nadeem Q. Mirza, receives stock and options as an inducement for employment.

John P. Hamill, SrVP/CFO/Prin Fin & Acct Ofcr of Aprea Therapeutics, reports acquisition of common stock and stock options.

Aprea Therapeutics' CEO, Oren Gilad, reports acquisition of common stock and stock options, signaling changes in his beneficial ownership.

John P. Hamill, SrVP/CFO/Prin Fin & Acct Ofcr of Aprea Therapeutics, Inc., purchased 1,010 shares of common stock and acquired Tranche A and B warrants on March 13, 2024.

Director Bernd R. Seizinger acquired common stock and warrants of Aprea Therapeutics, Inc. on March 13, 2024.

Director John B Henneman III reports acquisition of Aprea Therapeutics common stock and warrants on March 13, 2024.

Aprea Therapeutics' CEO, Oren Gilad, recently purchased 2,000 shares of common stock and acquired Tranche A and B warrants.